As the FDA and NIH eschew animal testing, startup raises $40 million for lab-grown organs
Vivodyne could capitalize on the desire for new approaches to preclinical research
Vivodyne co-founder and CEO Andrei Georgescu and Chief Operating Officer Julie O’Shaughnessy are seen here with the system the company designed.
The world looked a little different when bioengineer Dan Huh first began exploring whether it was possible to replace mouse testing with small-scale replicas of human tissues.
The iPhone was just hitting store shelves. The researchers who had discovered gene silencing through RNA interference had recently received a Nobel Prize. And a blonde, curly haired young woman by the name of Taylor Swift had just released her first album.